GlassScriptPhysician profile
Susan S Chi
NPI 1225146913
$1,534.71
in general payments reported to CMS, 2019-2025
23 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $81.38 · 2021: $78.01 · 2022: $271 · 2023: $196 · 2024: $282 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.13 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $226.79 | 2019-2025 | |
| Abbvie INC. | $181.86 | 2019-2022 | |
| Daiichi Sankyo INC. | $164.29 | 2019-2022 | |
| Coopersurgical, INC. | $117.40 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Mayne Pharma Commercial LLC | $114.63 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $109.39 | 2025 | |
| Pfizer INC. | $93.82 | 2024-2025 | |
| Hologic Sales and Service, LLC | $86.79 | 2019-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $76.87 | 2023-2025 | Veozah |
| Organon LLC | $46.14 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $44.12 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $43.43 | 2021-2022 | |
| Therapeuticsmd, INC. | $39.09 | 2019-2022 | |
| Biogen, INC. | $29.09 | 2025 | Zurzuvae |
| Davol INC. | $23.75 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $23.44 | 2019 | |
| Smith+Nephew, INC. | $18.39 | 2024 | Stravix |
| Pacira Pharmaceuticals Incorporated | $18.25 | 2024 | Exparel |
| Baxter Healthcare | $18.19 | 2025 | Perclot |
| Pharmacosmos Therapeutics INC. | $15.41 | 2023 | Monoferric |
| Mycovia Pharmaceuticals, INC. | $15.15 | 2023 | Vivjoa |
| Medicem INC. | $14.85 | 2023 | |
| Mission Pharmacal Company | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.